Phase 2 TNBC Clinical Trials
45 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 45 trials
Recruiting
Phase 2
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
TNBC - Triple-Negative Breast CancerBrain Metastasases
Fudan University58 enrolled1 locationNCT07638852
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Brain MetastasisTNBC
Fudan University24 enrolled1 locationNCT07623577
Recruiting
Phase 1Phase 2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Jiangsu Cancer Institute & Hospital34 enrolled1 locationNCT07601178
Recruiting
Phase 2
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Triple Negative Breast Cancer(TNBC)
The First Affiliated Hospital with Nanjing Medical University58 enrolled1 locationNCT07394387
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Breast CancerNode-positive Breast CancerHER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center32 enrolled1 locationNCT07276880
Recruiting
Phase 1Phase 2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Breast CancerTriple Negative Breast Cancer(TNBC)Residual Disease+1 more
UNC Lineberger Comprehensive Cancer Center78 enrolled1 locationNCT07069595
Recruiting
Phase 2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 2
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Triple-Negative Breast CancerTNBC - Triple-Negative Breast Cancer
Swiss Cancer Institute61 enrolled9 locationsNCT06358573
Recruiting
Phase 2
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Breast CancerTriple Negative Breast Cancer(TNBC)Early Stage Breast Cancer+2 more
Sun Yat-sen University192 enrolled5 locationsNCT06768931
Recruiting
Phase 1Phase 2
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Colorectal, CancerOvarian CancerCervical Cancer+7 more
Radiopharm Theranostics, Ltd61 enrolled4 locationsNCT07189871
Recruiting
Phase 2
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven356 enrolled10 locationsNCT06831955
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
HER2-positive Breast CancerTriple Negative Breast Cancer(TNBC)Breast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750